Status:
RECRUITING
Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients
Lead Sponsor:
University of Pisa
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Brief Summary
BACKGROUND AND RATIONALE. The role of type I interferons (IFN) in innate and adaptive immunity has been extensively studied, establishing a key role for type I IFNs in immune homeostasis. With growing...
Eligibility Criteria
Inclusion
- Patients diagnosed with SLE according to classification criteria valid at diagnosis time (1997, 2012, 2019)
- Written informed consent
- Active disease for which the patient is a candidate for Anifrolumab treatment (including compassionate use)
- Active disease for which the patient has started Anifrolumab treatment
Exclusion
- Age \<18 years
- Absence of patient consent
Key Trial Info
Start Date :
May 25 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2031
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT07215754
Start Date
May 25 2023
End Date
May 1 2031
Last Update
October 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pisa
Pisa, Italy, 56100